BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger

BioCryst Pharmaceuticals (NASDAQ:BCRX), and Idera Pharmaceuticals (NASDAQ:IDRA), today announced that they have signed a definitive merger agreement to form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases.
As quoted in the press release:

“Both of our companies have aspired to become successful providers of therapeutics for patients suffering from rare life-threatening diseases.  Both share a culture that puts patients first and keeps their interests at the very core of what we do, and how we do it,” stated Vincent Milano, Idera’s Chief Executive Officer.  “By merging our unique talents, experiences and assets, we instantly strengthen our ability to become a significant force for patients suffering from a broad range of rare diseases.  We will also gain operational synergies and strengthen our financial position.”

Click here to read the full press release.